82835-13-0

Basic information

• Product Name: (R)-2-TERT-BUTOXYCARBONYLAMINO-3-(2-CYANO-ETHYLSULFANYL)-PROPIONIC ACID METHYL ESTER
• Synonyms: (R)-2-TERT-BUTOXYCARBONYLAMINO-3-(2-CYANO-ETHYLSULFANYL)-PROPIONIC ACID METHYL ESTER
• CAS NO: 82835-13-0
• Molecular Formula: C12H20N2O4S
• Molecular Weight: 288.3632
• Mol File: 82835-13-0.mol

Chemical Properties

• Boiling Point: 462.6±45.0 °C(Predicted)
• Appearance: /
• Density: 1.152±0.06 g/cm3(Predicted)
• PKA: 10.70±0.46(Predicted)
• CAS DataBase Reference: (R)-2-TERT-BUTOXYCARBONYLAMINO-3-(2-CYANO-ETHYLSULFANYL)-PROPIONIC ACID METHYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-2-TERT-BUTOXYCARBONYLAMINO-3-(2-CYANO-ETHYLSULFANYL)-PROPIONIC ACID METHYL ESTER(82835-13-0)
• EPA Substance Registry System: (R)-2-TERT-BUTOXYCARBONYLAMINO-3-(2-CYANO-ETHYLSULFANYL)-PROPIONIC ACID METHYL ESTER(82835-13-0)

Safety Data

• Hazardous Substances Data: 82835-13-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Development:
(R)-2-TERT-BUTOXYCARBONYLAMINO-3-(2-CYANO-ETHYLSULFANYL)-PROPIONIC ACID METHYL ESTER is used as a building block for the synthesis of new pharmaceuticals due to its unique structural features, including the Boc protecting group, cyano group, and ethylsulfanyl group. These characteristics allow for its potential use in creating novel drug candidates with specific therapeutic properties.
Used in Medicinal Chemistry Research:
In the field of medicinal chemistry, (R)-2-TERT-BUTOXYCARBONYLAMINO-3-(2-CYANO-ETHYLSULFANYL)-PROPIONIC ACID METHYL ESTER serves as a valuable compound for studying the effects of its structural elements on biological activity. Its use in research can lead to a better understanding of how these groups contribute to the overall pharmacological profile of the resulting drug molecules.
Used in Drug Design and Optimization:
(R)-2-TERT-BUTOXYCARBONYLAMINO-3-(2-CYANO-ETHYLSULFANYL)-PROPIONIC ACID METHYL ESTER is used as a starting point for drug design and optimization processes. Its unique functional groups can be modified or used as a template to create new compounds with improved pharmacokinetic and pharmacodynamic properties, potentially leading to more effective treatments for various diseases and conditions.

Upstream product

• 20887-95-0 N-(tert-Butyloxycarbonyl)-L-cysteine 
• 172749-96-1 N-[(tert-butoxy)carbonyl]-L-cysteine methyl ester 
• 107-13-1 acrylonitrile 

Relevant articles and documents

L-cysteine, a versatile source of sulfenic acids. Synthesis of enantiopure alliin analogues

(Chemical Equation Presented) L-Cysteine is a stimulating starting product for the generation of transient sulfenic acids, such as 4, 6, 9, and 15, which add to suitable acceptors, allowing formation of sulfoxides showing a biologically active residue. These sulfoxides are easily isolated in enantiomerically pure form. For instance, N-(tert-butoxycarbonyl)-L-cysteine methyl ester (1a) furnished in few steps sulfenic acid 9a, which was readily converted into (R,SS)-(2-tert-butoxycarbonylamino-2-methoxycarbonyl- ethylsulfinyl)ethene (22), the methyl ester of Boc-protected nor-alliin. Moreover, the addition of 9a to 2-methyl-1-buten-3-yne has led to a sulfur epimeric and separable mixture of (CR)-2-(2-tert-butoxycarbonylamino-2- methoxycarbonyl-ethylsulfinyl)-3-methyl-buta-1,3-dienes 10a and 11a, still possessing a "masked" sulfenic acid function, producible from their cysteine moieties once the dienes have been converted into the desired derivatives.

Sulfenic acids from L-cysteine involved in the synthesis of alliin analogues

L-cysteine is a stimulating starting product for the generation of transient sulfenic acids that add to suitable acceptors, allowing formation of sulfoxides showing a biologically active residue. For instance, N-(tert-butoxycarbonyl)-L-cysteine methyl ester furnished in few steps (R)-2-tert-butoxycarbonylamino-2-methoxycarbonyl-ethanesulfenic acid, which was readily converted into (R,SS)-(2-tert-butoxycarbonylamino-2- methoxycarbonyl-ethylsulfinyl)ethene, the methyl ester of Boc-protected nor-alliin. Copyright Taylor & Francis Inc.